Is there a role for incorporating local therapy into the management of oligometastatic EGFR-mutant NSCLC with curative intent?

Topics: Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Yale

If so, what is your approach to sequencing and timing of targeted therapy and local therapy?

Answer from: Medical Oncologist at Community Practice

I don’t think there is such a thing as curative intent oligometastatic therapy. That said, consolidative SBRT to 1-3 safe lesions for osimertinib responders seems very reasonable

Comments

Medical Oncologist at Gerard J Ventura MD, FACP
What about a more common situation- a patien...

Related Questions